Detalhe da pesquisa
1.
BRCA1 Mutational Complementation Induces Synthetic Viability.
Mol Cell
; 78(5): 951-959.e6, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359443
2.
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Proc Natl Acad Sci U S A
; 110(42): 17041-6, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24085845
3.
Discovery of new glomerular disease-relevant genes by translational profiling of podocytes in vivo.
Kidney Int
; 86(6): 1116-29, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24940801
4.
Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities.
Nat Commun
; 14(1): 7714, 2023 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001070
5.
Genetic variation in APOL1 associates with younger age at hemodialysis initiation.
J Am Soc Nephrol
; 22(11): 2091-7, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21997398
6.
RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage.
Nat Commun
; 12(1): 5016, 2021 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34408138
7.
A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9.
Kidney Int
; 78(7): 698-704, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20668430
8.
RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers.
Cancer Res
; 80(13): 2848-2860, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32213544
9.
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
Mol Cancer Ther
; 19(2): 602-613, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31575654
10.
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
Nat Commun
; 10(1): 5661, 2019 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31827092
11.
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Cell Rep
; 24(13): 3513-3527.e7, 2018 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30257212
12.
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Cell Rep
; 23(11): 3127-3136, 2018 06 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898385
13.
Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Oncotarget
; 7(47): 76590-76603, 2016 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27740936
14.
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
J Clin Invest
; 126(8): 3145-57, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27454289
15.
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Cell Rep
; 17(9): 2367-2381, 2016 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27880910
16.
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Cancer Res
; 76(9): 2778-90, 2016 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27197267
17.
Copy Number Variation at the APOL1 Locus.
PLoS One
; 10(5): e0125410, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25933006
18.
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Cell Rep
; 25(5): 1384, 2018 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30380426
19.
Association of trypanolytic ApoL1 variants with kidney disease in African Americans.
Science
; 329(5993): 841-5, 2010 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-20647424